Qure.ai vs ScreenPoint Transpara

ScreenPoint's Transpara has a randomized trial behind it. ScreenPoint says Transpara was the AI in MASAI, a Lund University randomized study published in the Lancet, and reports more than 105,000 women with sensitivity of 80.5% against 73.8% for standard double reading at 98.5% specificity. It also cites a 29% rise in cancer detection and a 44% cut in workload, drawn from separate analyses. The vendor calls Transpara vendor agnostic across FFDM and DBT systems, and a density tool is cleared under K232096. A program that double-reads screening mammograms matches the Swedish MASAI setting.

Qure's qXR chest X-ray tools, qER head CT triage and qCT lung nodule volumetry fit a hospital imaging department or a TB program, and the vendor reports registration in more than 85 countries. Screening mammography and chest or head CT sit in separate reading rooms, so the two tools reach separate buyers.